According to a recent LinkedIn post from SurGenTec, the company is drawing attention to new peer-reviewed data on its OsteoFlo HydroFiber synthetic bone graft published in the Global Spine Journal. The publication reportedly covers a large, independently conducted study using the Boden Spine Model to assess posterolateral spinal fusion with multiple imaging and histologic endpoints.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that HydroFiber achieved fusion outcomes equivalent to autograft and that adding autograft did not further improve results, positioning the product as a potential standalone alternative to the traditional gold standard. For investors, these findings may support SurGenTec’s value proposition in spinal fusion and trauma indications, potentially strengthening reimbursement arguments and competitive positioning in the orthopedic and spine surgery device market.
As shared in the post, HydroFiber is described as FDA-cleared as equivalent to autograft for use across cervical, thoracic, and lumbar procedures, including disc spaces, interbody cages, and lateral gutters, as well as trauma and bone void filling related to osteomyelitis, tumors, and cysts. Broader clinical utility and positive study data could enhance adoption prospects, support pricing power relative to other synthetic grafts, and improve the company’s longer-term revenue growth potential if market penetration increases.